chevron_leftBack
As of 24 April 2025, Aspire Biopharma Holdings, Inc. has a market cap of $24.23M USD, ranking #28819 globally and #6 in Puerto Rico. It ranks #2879 in the Healthcare sector, and #946 in the Biotechnology industry.
Key Stats
Market Cap
$24.23MUSD
Enterprise Value
$25.07MUSD
Net Income (TTM)
-$648.16KUSD
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Kraig Higginson
open_in_new
Employees
0
Founded
2021
Website
aspirebiolabs.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -1.7% | -5.7% | -18% | -95% | -96% | -95% |
Upcoming Earnings
Earnings Date
Sat, May 24
Earnings Time
sunny
Before Open
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
ASBP
Aspire Biopharma Holdings Inc
ISIN: US7389201077
Shares Out.:
Shares Outstanding:
48.901M1
Shares Float:
36.955M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
0.5200 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Aspire Biopharma Holdings, Inc.
Aspire Biopharma Holdings, Inc., early-stage biopharmaceutical company, engages in developing and marketing of disruptive technology for delivery mechanisms for do no harm drugs in the United States. The company provides Sublingual Aspirin Product, which addresses cardiology emergencies and pain management. It develops formulation for a sublingually administered melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide, as well as formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and several other classes of drugs. The company was founded in 2021 and is based in Humacao, Puerto Rico.
